Immunotherapy for Hepatocellular Carcinoma

Recruiting now

Conditions studied: Hepatocellular Carcinoma, Immunotherapy

In brief

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Key facts

Study ID

NCT06241326

Run by

The First Affiliated Hospital with Nanjing Medical University

People needed

11000

Starts

2024-03-01

Expected to finish

2026-12-31

Last updated by the study team

2024-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged after 18 years (18 is included).
• Hepatocellular carcinoma diagnosed by pathology or imaging.
• Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
• For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
• Patients voluntarily enroll in this study.

You may not qualify if…

• Pregnant or lactating women.
• Other conditions regimented at investigators' discretion.

Where it is running

• Jiangsu Province Hospital — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.